Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination
Pilot Study Testing the Immunogenic Efficacy of an Edible Vaccine for Hepatitis B in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All Roswell Park Cancer Institute (RPCI) staff, faculty, and students, who are in good health
- Participants confirmation of history of primary immunization series with recombinant hepatitis B (HB) vaccine (last dose at least one year prior to screening anti-HBs level assessment)
- Current anti-HBs levels less than or equal to 115 mIU/mL
- Major organ functions within acceptable medical limits as determined in routine clinical laboratory screening tests
- Expected availability for the duration of the study period
- If female, then documentation that the subject is not pregnant by an acceptable laboratory test and that the subject is using an adequate birth control method to prevent pregnancy for at least 3 months following the last immunization in the study
- Human immunodeficiency virus (HIV) antibody negative
- Ability to provide written informed consent
- Supervisor approval
Exclusion Criteria:
- Known history of allergy or hypersensitivity to potato, potato components or potato products
- Known history of allergy to hepatitis B vaccine in any form or to components of hepatitis B vaccine
- Pregnancy or breast feeding
- Current anti-HBS levels greater than 115 mIU/mL
- Known immunodeficiency, cancer, or use of immunosuppressive medication including cancer chemotherapy and systemic steroids (excluding intermittent use of topical steroids)
- Participation in another investigational study within 30 days of enrollment in this study
- Known and currently active gastrointestinal disease including any of the following: peptic ulcer disease, gastroesophageal reflux, inflammatory bowel disease, diverticulitis, or pancreatitis
- Use of prescription medication or over the counter H2 blockers or proton pump inhibitors (PPIs) for any of the above diseases regularly and within 1 month of enrollment
- Diagnosis of insulin-dependent diabetes or multiple sclerosis
- Significant laboratory abnormality which suggests dysfunction of hematological, renal, or hepatic systems
- Known history of hepatitis B infection in the past
- Temporary exclusion for mild upper respiratory illness, gastrointestinal illness, or other febrile episode that is expected and documented to resolve
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Arm I
Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
|
Correlative studies
Other Names:
Given orally (PO)
Other Names:
|
|
Experimental: Arm II
Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
|
Correlative studies
Other Names:
Given orally (PO)
Other Names:
Given PO
Other Names:
|
|
Experimental: Arm III
Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
|
Correlative studies
Other Names:
Given orally (PO)
Other Names:
Given PO
Other Names:
|
|
Experimental: Arm IV
Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
|
Correlative studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum fold increase in anti-HBsAg titer levels relative to baseline levels
Time Frame: Over 70 days
|
Over 70 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absolute maximum response
Time Frame: On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114
|
On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114
|
|
Area under the curve
Time Frame: On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114
|
On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114
|
|
Proportion of two-fold responses in anti-HBsAg titer levels
Time Frame: On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114
|
On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- I 124207
- NCI-2011-00064 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.